logo
Sign in

PROGNOSYS BIOSCIENCES, INC.

Biotech · Private

Multiplexed gene expression analysis technology for parallel sample processing

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$1.6M
Federal grants
$1.6M
3 awards · 2015
Rank in peer group#19 of 32
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
23
17 pending · first 2022
Rank in peer group#1 of 32

Capital timeline

2015FEDERAL ↑EQUITY ↓Cumulative $1.6M$347K$559K$713K
2015FEDERAL ↑EQUITY ↓Cumulative $1.6M$347K$559K$713K

Latest events

  • Federal grantHealth and Human S · Phase II · Multiplexed Nucleic Acid Assays$713K
  • Federal grantHealth and Human S · Phase II · Highly Multiplexed Digital Assays$559K
  • Federal grantHealth and Human S · Phase I · Multiplexed Protein Assays$347K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 32 peers

Line = median

Biotech · Instrument

  • Federal grantsBelow median
  • Granted patents#1 · top 3%
  • Linked publications#2 · top 6%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 23 granted of 40
Show all 40 patent records

Recent research by its founders

  • 1310 Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight20250 cites
  • Computer-aided visualization and analysis system for sequence evaluation20230 cites
  • Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses2021220 cites

Related companies, and why

  • SAPHTX, INC.Similar federal contract value in Biotech · null in contracts
  • SYRACUSE BIOLABS, INC.Similar federal contract value in Biotech · null in contracts
  • DualitasSimilar federal contract value in Biotech · null in contracts
  • OnKure, Inc.Similar federal contract value in Biotech · null in contracts
  • LUMINARY THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
  • Numab TherapeuticsSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .